🔍

Vivanta Industries Ltd (541735)

📊 BSE: 541735 🏢 Civil Construction 📢 Latest filing: 08 Oct 2026

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Vivanta Industries' revenue was ₹80.2 Cr (+5.7% year on year, +109.7% on the previous quarter), and net profit ₹1.0 Cr (+84.9% year on year); the operating margin was 0.6%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹80.2	+5.7%	+109.7%
Operating profit	₹0.5	from loss	from loss
Net profit	₹1.0	+84.9%	from loss
EPS (₹)	0.08	+100.0%	from loss
Operating margin	0.6%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Vivanta Industries: Statement of Deviation Under Reg 32 Not Applicable for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Oct 2026, 11:18 AM

Vivanta Industries Limited has submitted a regulatory disclosure confirming the non-applicability of the Statement of Deviation or Variation under Regulation 32 of SEBI LODR Regulations. The company reported that it has not raised any funds via Public Issue, Rights Issue, or Preferential Issue. Consequently, no deviation reporting is required for the period. This is a standard compliance filing confirming no fresh equity dilution or issue proceeds utilization.

Filing submitted under Regulation 32 of SEBI LODR Regulations on October 8, 2026
Confirmed zero funds raised via Public Issue, Rights Issue, or Preferential Issue
Statement of Deviation or Variation not applicable for the period
Reference to SEBI Circular No. CIR/CFD/CMD1/162/2019 dated 24th December, 2019

💡 Track the upcoming quarterly financial results for operational updates, as this filing is purely procedural.

Vivanta Industries CS and Compliance Officer Devang Shah Resigns Effective Oct 1, 2026

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 01 Oct 2026, 02:23 PM

Vivanta Industries announced the resignation of Mr. Devang Shah from his position as Company Secretary, Compliance Officer, and Key Managerial Personnel. The resignation is effective from the close of business hours on October 1, 2026. The departure is attributed to personal reasons and pursuing career opportunities outside the company, with no other material reasons cited. This administrative departure affects a micro-cap company with a market cap of Rs 21 Cr and FY26 revenue of Rs 250.1 Cr.

Devang Shah stepped down as Company Secretary & Compliance Officer on October 1, 2026
Cessation takes effect from the close of business hours on October 1, 2026
Reason cited is pursuing career opportunities outside the company with no other material reasons

💡 Track subsequent exchange filings for the appointment of a new Company Secretary and Compliance Officer within the statutory timeline.

Vivanta Industries Adopts New MOA and AOA Aligned with Companies Act 2013

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Sep 2026, 04:57 PM

Vivanta Industries announced shareholder approval at its 13th AGM on September 30, 2026, to adopt a new set of Memorandum of Association (MOA) and Articles of Association (AOA). The amendments align the corporate charter with the Companies Act, 2013, replacing references from the erstwhile Companies Act, 1956. The main objects under Clause III (A) remain unchanged, with alterations primarily restructuring incidental objects and liability clauses to standard statutory formats.

Shareholders approved adoption of new MOA and AOA at the 13th AGM held on September 30, 2026
Existing Clause III (B) replaced with matters necessary for furtherance containing sub-clauses 1 to 99
No changes made to Clause III (A) containing the core Main Objects (sub-clauses 1 to 3)
Adoption aligns statutory charter from Companies Act 1956 to Companies Act 2013 Table-A and Table-F formats

💡 Track subsequent statutory filings with the Registrar of Companies (ROC) and monitor quarterly financial performance.

Vivanta Industries Board to Meet Sept 2, 2026 for AGM, Borrowing Limits & RPT Approvals

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 27 Aug 2026, 06:34 PM

Vivanta Industries has scheduled a Board of Directors meeting on September 2, 2026, to approve the Board's Report and Secretarial Audit Report for FY 2025-2026 and convene its 13th Annual General Meeting (AGM). The agenda also includes approving material Related Party Transactions for FY 2026-2027, revising borrowing limits under Section 180(1)(c), and approving loans/investments under Sections 185 and 186. Additionally, the Board will consider adopting updated Memorandum and Articles of Association under the Companies Act, 2013.

Board meeting scheduled for September 2, 2026, at the company's registered office
Approval of Board's Report, Secretarial Audit Report, and FY26 Financial Statements
Proposal to revise borrowing authority under Section 180(1)(c) and approve loans under Sections 185 and 186
Review and approval of material Related Party Transactions for FY 2026-2027
Appointment of M/s. Jitendra Parmar & Associates as scrutinizer for the 13th AGM

💡 Track the outcome of the September 2, 2026 board meeting for specifics on revised borrowing limits and the quantum of proposed related party transactions.

Vivanta Industries Confirms Zero Funds Raised via Public or Preferential Issues

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 01 Aug 2026, 02:05 PM

Vivanta Industries Ltd has filed a statement of non-applicability regarding Regulation 32 of SEBI (LODR) Regulations. The company confirmed that it has not raised any funds through Public Issues, Rights Issues, Preferential Issues, or Qualified Institutions Placements (QIP) during the period. Consequently, there are no deviations or variations in fund utilization to report. This is a standard administrative filing required for regulatory compliance.

Confirmed zero funds raised through Public, Rights, or Preferential Issues
Statement of Deviation or Variation is not applicable as per SEBI Circular dated 24th December 2019
Compliance filing submitted to BSE on August 1, 2026
No change in capital structure reported through these specific fundraising routes

💡 No action is required as this is a routine procedural filing. Investors should focus on upcoming operational results for performance cues.

Vivanta Industries Approves Q1 FY27 Results; Announces Qness Pharma Collaboration

🟡 NEUTRAL ⭐ 5/10

EARNINGS 📅 29 Jul 2026, 04:43 PM

Vivanta Industries approved its unaudited financial results for the quarter ended June 30, 2026, during its board meeting on July 29, 2026. While specific Q1 figures were not detailed in the summary text, the company announced a new business collaboration with Qness Pharmaceuticals for manufacturing, branding, and marketing. This comes after a fiscal year (FY26) where the company achieved Rs 250 Cr in revenue but maintained a very thin PAT of Rs 1 Cr. The board also authorized opening a trading and demat account with Motilal Oswal, indicating active treasury or investment management.

Approved standalone and consolidated financial results for the quarter ended June 30, 2026.
Executed a business collaboration agreement with Qness Pharmaceuticals for pharma product supply and marketing.
Company operates with a low promoter holding of 10.6% as of March 2026.
Reported TTM revenue of Rs 250 Cr against a small market capitalization of only Rs 19 Cr.
Debt levels remain significant at Rs 18 Cr, resulting in a Debt-to-Equity ratio of 1.00.

💡 Investors should examine the detailed Q1 FY27 financial tables to see if the negative operating margins (-0.8% TTM) have improved. Monitor for further disclosures regarding the financial terms and expected revenue contribution from the Qness Pharmaceuticals collaboration.

Vivanta Industries Approves Q1 FY27 Results and Announces Pharma Business Collaboration

🔵 WATCH ⭐ 6/10

BOARD_MEETING 📅 29 Jul 2026, 04:31 PM

Vivanta Industries approved its unaudited financial results for the quarter ended June 30, 2026, in a board meeting held on July 29, 2026. A key development is the board's note on a business collaboration agreement with Qness Pharmaceuticals for the manufacture, supply, and marketing of pharmaceutical products. The company also authorized opening a trading and demat account with Motilal Oswal Financial Services. Despite a high TTM revenue of ₹250 Cr, the company operates with a very small market cap of ₹19 Cr and thin margins.

Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026
Executed a business collaboration agreement with Qness Pharmaceuticals for branding and marketing of allied products
Authorized the opening of a Trading and Demat Account with Motilal Oswal Financial Services Limited (MOFSL)
Promoter holding remains low at 10.6% as per the latest March 2026 filings
Company reported a TTM revenue of ₹250 Cr against a market capitalization of only ₹19 Cr

💡 Investors should closely examine the full Q1 FY27 financial tables once published to see if margins have improved from the -0.8% TTM OPM. Monitor for further disclosures regarding the financial terms and expected revenue from the Qness Pharmaceuticals collaboration.

Vivanta Industries Reschedules Board Meeting to July 29, 2026, to Discuss Q1 Results and M&A

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 24 Jul 2026, 04:57 PM

Vivanta Industries has rescheduled its board meeting from July 24 to July 29, 2026, citing heavy rainfall and adverse weather conditions. The board will meet to approve the unaudited financial results for the quarter ended June 30, 2026, and sign the audited statements for FY26. Additionally, the agenda includes a business collaboration agreement with Qness Pharmaceuticals for the manufacture and marketing of pharmaceutical products. This is significant as the company currently operates in civil construction with thin TTM margins of -0.8% and a low promoter holding of 10.6%.

Board meeting rescheduled from July 24, 2026, to July 29, 2026.
Agenda includes approval of financial results for the quarter ended June 30, 2026.
Board to consider a business collaboration agreement with Qness Pharmaceuticals.
Authorization of signatories for FY26 audited financial statements (year ended March 31, 2026).
Company reports TTM revenue of ₹250 cr against a small market cap of ₹19 cr.

💡 Investors should monitor the July 29 results to see if the company can reverse the ₹0.8 cr loss reported in the March 2026 quarter. Further details on the Qness Pharmaceuticals collaboration are needed to assess if this represents a material diversification from its core civil construction business.

Vivanta Industries Board Meeting on July 24 to Approve Q1 Results and Pharma Collaboration

🔵 WATCH ⭐ 5/10

BOARD_MEETING 📅 21 Jul 2026, 01:24 PM

Vivanta Industries has scheduled a board meeting for July 24, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. Crucially, the board will also take note of a business collaboration agreement with Qness Pharmaceuticals for the manufacture, branding, and marketing of pharmaceutical products. This comes at a time when the company's TTM revenue stands at ₹250 Cr but with thin margins (OPM -0.8%) and a low promoter holding of 10.6%. Investors should watch for details on the pharma venture's scale relative to their existing civil construction business.

Board meeting scheduled for July 24, 2026, to approve Q1 FY27 financial results.
Agenda includes noting a business collaboration with Qness Pharmaceuticals for pharma and allied products.
Authorization of signatories for the financial statements of the year ended March 31, 2026.
Company reports a low promoter holding of 10.6% as of March 2026.
TTM revenue of ₹250 Cr contrasts with a small market capitalization of only ₹20 Cr.

💡 Monitor the July 24 board meeting outcome for specific financial terms of the Qness Pharmaceuticals collaboration and any shift in business strategy from civil construction to pharma.

View All 541735 Announcements on Live Market Tracking →